License Agreements and Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedules of tables providing amounts included in the company's condensed consolidated statements of operations and comprehensive loss attributable to transactions arising from its collaborative arrangements

The following tables provide amounts by year indicated and by line item included in the Company's accompanying consolidated financial statements attributable to transactions arising from its license and collaboration arrangements. The dollar amounts in the tables below are in thousands.




	2003 Sandoz Agreement		2006 Sandoz Agreement			Mylan Collaboration Agreement			CSL Collaboration Agreement			Total
Contract assets
Collaboration receivables:
December 31, 2019	$	—	$	8,013		$	—		$	—		$	8,013
Revenue / cost recovery	—		8,697			(4		)	—			8,693
Cash receipts	—		(118		)	—			—			(118		)
Reclassification to collaboration liabilities	—		—			4			—			4
March 31, 2020	$	—	$	16,592		$	—		$	—		$	16,592

Contract liabilities
Deferred revenue:
December 31, 2019	$	—	$	—		$	1,835		$	—		$	1,835
Revenue recognition	—		—			(192		)	—			(192		)
March 31, 2020	—		—			1,643			—			1,643
Less: current portion	—		—			(748		)	—			(748		)
Deferred revenue, net of current portion - March 31, 2020	$	—	$	—		$	895		$	—		$	895

Collaboration liabilities:
December 31, 2019	$	—	$	—		$	3,142		$	981		$	4,123
Payments	—		—			—			(981		)	(981		)
Net collaboration costs incurred in the period	—		—			(1,979		)	803			(1,176		)
March 31, 2020	$	—	$	—		$	1,163		$	803		$	1,966



	Three Months Ended March 31, 2020
	2003 Sandoz Agreement		2006 Sandoz Agreement		Mylan Collaboration Agreement			CSL Collaboration Agreement		Total
Product revenue	$	—	$	8,692	$	—		$	—	$	8,692
Research and development revenue	—		5		192			—		197
Total collaboration revenue	$	—	$	8,697	$	192		$	—	$	8,889
Operating expenses:
Research and development expense	$	—	$	2	$	7,481		$	15	$	7,498
General and administrative expense	90		—		177			2		269
Net amount (recovered from) / payable to collaborators	—		—		(1,979		)	803		(1,176		)
Total operating expenses	$	90	$	2	$	5,679		$	820	$	6,591



	Three Months Ended March 31, 2019
	2003 Sandoz Agreement		2006 Sandoz Agreement		Mylan Collaboration Agreement			CSL Collaboration Agreement		Total
Product revenue	$	—	$	2,352	$	—		$	—	$	2,352
Research and development revenue	—		420		1,341			—		1,761
Total collaboration revenue	$	—	$	2,772	$	1,341		$	—	$	4,113
Operating expenses:
Research and development expense	$	—	$	54	$	2,778		$	58	$	2,890
General and administrative expense	4,300		25		268			9		4,602
Net amount (recovered from) / payable to collaborators	—		—		(139		)	1,282		1,143
Total operating expenses	$	4,300	$	79	$	2,907		$	1,349	$	8,635

MOMENTA PHARMACEUTICALS INC 10-Q